Tamsulosin Hydrochloride Capsule
Product Images NDC 51655-832

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 51655-832). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 832 52 Master Bottle Label Approval Rev A 02 22)

Label for Tamsulosin Hydrochloride capsules, USP 0.4 mg, containing 30 capsules. The label includes storage instructions to keep the product at 20°-25°C (68°-77°F) in the original container, out of reach of children, and avoiding excessive moisture. The product is Rx only and manufactured by Northwind Health Company, LLC.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours following a single 0.4 mg oral dose under fasted and fed conditions in 8 subjects. The y-axis indicates plasma concentration in ng/mL, and the x-axis indicates time in hours. The fasted condition shows a higher and earlier peak concentration compared to the fed condition.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph showing the mean change from baseline in total AUA symptom score over a 13-week treatment period with Tamsulosin Hydrochloride 0.4 mg and 0.8 mg compared to placebo. The y-axis represents mean change, and the x-axis shows treatment duration in weeks. Both Tamsulosin doses demonstrate greater symptom score reductions than placebo over time.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean change on the y-axis and duration of treatment in weeks on the x-axis. Three treatment groups are plotted: 0.8 mg, 0.4 mg, and placebo. The graph displays decreasing symptom scores over time for all groups, with 0.8 mg and 0.4 mg treatments showing greater symptom score reductions compared to placebo through 13 weeks.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in mL/sec on the y-axis and duration of treatment in weeks on the x-axis. It compares three treatment groups: 0.8 mg, 0.4 mg, and placebo, with sample sizes indicated below the x-axis. The graph plots the mean increase in peak urine flow rate over time for these groups.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in peak urine flow rate over a treatment duration of up to 18 weeks. The graph compares three groups: 0.8 mg treatment, 0.4 mg treatment, and placebo, plotted with different symbols and line styles. Mean changes increase over time for all groups, with 0.8 mg and 0.4 mg showing higher increases than placebo.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride showing its molecular composition and arrangement, including aromatic rings, ethoxy group, and hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.